Heart failure due to anlotinib
10.3760/cma.j.cn114015-20220720-00655
- VernacularTitle:安罗替尼致心力衰竭
- Author:
Yupei WU
1
;
Yuesong YIN
;
Qian WANG
;
Dongmiao WANG
;
Lina ZHANG
Author Information
1. 河北省人民医院药学部，石家庄 050051
- Publication Type:Journal Article
- Keywords:
Heart failure;
Drug-related side effects and adverse reaction;
Anlotinib
- From:
Adverse Drug Reactions Journal
2022;24(9):494-496
- CountryChina
- Language:Chinese
-
Abstract:
A 66-year-old female patient with infiltrating adenocarcinoma in left lung received anlotinib 12 mg orally once daily (2-week medication followed by 1-week discontinuation, 3 weeks was a cycle). After 14 months of regular medication, the patient developed palpitation and chest tightness. Laboratory tests showed that the N-Terminal pro-brain natriuretic peptid (NT-proBNP) was 1 698 ng/L; echocardiography showed decreased apical wall motion and left ventricular diastolic dysfunction. Heart failure was condsidered, which was suspected to be related to anlotinib. Anlotinib was stopped and symptomatic treatments were given. Eight days later, her symptoms above-mentioned were alleviated and NT-proBNP was 485 ng/L. Because of the illness condition, the patient took anlotinib again at original dose according to the doctor′s instructions. Three months later, the above symptoms recurred and ventricular fibrillation occurred suddenly. Considering that the heart failure in the patient might be caused by anlotinib. Anlotinib was stopped again. After 11 days of treatments with diuretics, cardiac function improvement, myocardial nutrition, and potassium supplement, the patient′s condition was improved obviously. After that, the patient did not take anlotinib again.
